TXMD News and Press, TherapeuticsMD Inc.

2026-05-12 16:24:44 ET More on Therapeutics MD Therapeutics MD reports FY results Historical earnings data for Therapeutics MD Financial information for Therapeutics MD Read the full article on Seeking Alpha For further details see: Therapeutics M...

TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the three months ended March 31, 2026. First Quarter 2026 Financial Results Net Income (L...

2026-03-30 16:15:55 ET More on Therapeutics MD Financial information for Therapeutics MD Read the full article on Seeking Alpha For further details see: Therapeutics MD reports FY results

TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the full year ended December 31, 2025. Full Year 2025 Financial Results Net Loss from Con...

2025-11-13 00:24:48 ET More on Therapeutics MD Seeking Alpha’s Quant Rating on Therapeutics MD Financial information for Therapeutics MD Read the full article on Seeking Alpha For further details see: Therapeutics MD GAAP EPS of $0.00

TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the three months ended September 30, 2025. Third Quarter 2025 Financial Results Net Incom...

2025-11-10 12:40:46 ET More on Pfizer Pfizer Gets Metsera: Why The $20.65 CVR Is Highly Likely To Pay Out (In Part) Healthcare Q3 Dividend Roundup: I Prefer AbbVie Over Pfizer Pfizer: The Storm Has Passed -- Tailwinds Ahead Key deals this week: ITV-Sky, Metse...

2025-08-12 16:44:42 ET More on Therapeutics MD Financial information for Therapeutics MD Read the full article on Seeking Alpha For further details see: Therapeutics MD GAAP EPS of $0.05

TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the three months ended June 30, 2025. Second Quarter 2025 Financial Results Net Income (L...

Xenon Pharmaceuticals Inc. (XENE) is expected to report $-1.03 for Q2 2025 Gaia Inc. (GAIA) is expected to report $-0.08 for Q2 2025 Insight Molecular Diagnostics Inc. (IMDX) is expected to report for Q2 2025 Lightbridge Corporation (LTBR) is expected to report for Q2 2025 NewHold...